Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant chemotherapy for resected small bowel adenocarcinoma
ISRCTN15070952Phase 3Active, not recruiting
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Aug 2015
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of capecitabine, fluorouracil, folinic acid and oxaliplatin in small bowel adenocarcinoma (SBA) (4 arms), sponsored by NHS Greater Glasgow and Clyde. Primary endpoint: Disease-free survival. Started Aug 2015; status: active, not recruiting.
02
Drugs
capecitabinefluorouracilfolinic acidoxaliplatin
03
Conditions
small bowel adenocarcinoma (SBA)
Beyond the preview
Go deeper on ISRCTN15070952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15070952.